Biotech Values

[DewDiligence]

GILD, MRK pause phase-2 trial of weekly Islatravir/Lenacapavir to consider protocol amendments, pursuant to MRK’s recent discontinuation of MK-8507 (#msg-166830983):

https://www.gilead.com/news-and-press/company-statements/gilead-and-merck-announce-temporary-pause-in-enrollment-for-phase-2-study-evaluating-an-oral-weekly-combination-regimen-of-investigational-islatravir-and-investigational-lenacapavir

The trial that led to MRK’s dropping MK-8507 was testing the combination of MK-8507 and included Islatravir. Although MRK says Islatravir did not play a role in the observed safety problem, it sounds like GILD is not fully convinced.